(Photo: Left: Professor Shen Hao, CEO of Biosyngen; Right: Professor Shi Yuanyuan, Founder of Deep Harbour Cell Valley)

Focusing on Solid Tumor Cell Therapy, Promoting Joint Drug Development

On July 9, 2025,Professor Shen Hao, CEO of Biosyngen China, visited Deep Harbour Cell Valley and was warmly received by Professor Shi Yuanyuan, Founder of the company.

Both parties conducted in-depth discussions on innovative pipeline cooperation for cellular therapy targeting solid tumors and reached a preliminary consensus for collaboration. This meeting will facilitate deep integration between the two sides in terms of technology platform synergy, sharing of clinical resources, and regulatory filings in both China and the US, working together to create cell therapy achievements with greater international influence.

Company Introduction

Biosyngen was established in 2016, with its headquarters in Singapore and an international standard GMP manufacturing base in Guangzhou, China. The company focuses on the global development of three major immune cell therapies: CAR-T, TCR-T, and TIL, covering various indications including nasopharyngeal carcinoma, liver cancer, lung cancer, and gastrointestinal tumors.

Core Advantages 

·The world's first TIL product targeting all liver cancer types has entered clinical trials;

·Multiple pipelines have obtained Sino-US dual IND approvals;

·Established clinical collaborations with the National Cancer Centre Singapore and Sun Yat-sen University Cancer Center;

·Possesses proprietary T cell function enhancement platforms such as SUPER-T and MSE-T.

Biosyngen is committed to becoming a leading cell therapy enterprise in Asia with international excellence.